Singapore Blood Plasma Market, By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin, Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other) - Industry Trends and Forecast to 2030.
Singapore Blood Plasma Market Analysis and Size
The increasing demand for plasma-derived medicines acts as one of the major factors driving the market growth. The advancements in medical technology and increasing healthcare infrastructure expenditure accelerate the market growth.
Data Bridge Market Research analyzes that the Singapore blood plasma market, which was USD 1,108.80 million in 2022, would rocket up to USD 2,209.35 million by 2030, and is expected to undergo a CAGR of 9.00% during the forecast period. “Hyperimmune Globulin” segment is expected to dominate the type segment of the market owing to the advancements in technology that have led to the development of advancements in blood plasma products for various use.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Singapore Blood Plasma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin, Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other)
|
|
Countries Covered
|
Singapore
|
|
Market Players Covered
|
CSL Limited (Australia), Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), and Octapharma AG (Switzerland) among others
|
|
Market Opportunities
|
|
Market Definition
Plasma is the liquid component of the blood that contributes to 55% of the total volume of blood. Blood plasma is the yellowish liquid component of blood that remains after red blood cells, white blood cells, platelets, and other cellular components have been removed. It plays a crucial role in maintaining overall health and contains various proteins, antibodies, clotting factors, and nutrients.
Singapore Blood Plasma Market Dynamics
Drivers
- Increasing prevalence of chronic diseases
The rising incidence of chronic diseases such as cancer, autoimmune disorders, and hemophilia drives the demand for blood plasma-based therapies. Plasma-derived products such as Immunoglobulin, clotting factors, and albumin are essential for the treatment of these conditions.
- Growing aging population
Singapore has a growing aging population. Elderly individuals are more susceptible to various health conditions, including immune disorders and coagulation disorders. The need for blood plasma-based therapies increases with the aging population, thereby driving market growth.
- Technological advancements
Advances in technology have significantly improved the collection, processing, and storage of blood plasma. Automation, better testing methods, and increased efficiency in plasma fractionation processes have made plasma-derived products more accessible and reliable, driving market growth.
Opportunities
- Increased awareness and screening for blood-related diseases
Awareness campaigns, public health initiatives, and increased screening for blood-borne diseases have led to the identification of more individuals who require plasma-based therapies. This has created a larger patient pool and subsequently increased the demand for blood plasma products.
- Government support and regulations
The Singapore government plays a crucial role in regulating and promoting the Singapore blood plasma market. Favorable policies, regulations, and support for the development and distribution of plasma-derived products encourage market growth and investment in the sector.
Restraint
- Regulatory challenges
The Singapore blood plasma market is subject to stringent regulations and guidelines to ensure the safety and quality of the collected plasma. Compliance with these regulations can pose challenges for market participants, including obtaining necessary approvals, meeting quality standards, and adhering to safety protocols.
Challenge
- Limited donor pool
The availability of suitable blood plasma donors can be a restraint for market growth. The eligibility criteria for plasma donation can be quite restrictive, including factors such as age, health conditions, and previous medical history. This limited pool of eligible donors may impact the overall supply of blood plasma in the market.
The Singapore blood plasma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the company for a new era of growth. This strategy aims to bolster the company’s strong commercial portfolio with AUSTEDO, AJOVY, UZEDYTM, and biosimilars amplify its innovative pipeline, sustain its generics powerhouse, and focus on the business
- In November 2022, a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies and Sun Pharma Advanced Research Company Ltd
Singapore Blood Plasma Market Scope
The Singapore blood plasma market is segmented into five notable segments based on type, mode of delivery, therapeutic indication, application, and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Hyperimmune Globulin
- Albumin
- Factor VIII
- Factor IX
- Immunoglobulin
- Others
Mode of Delivery
- Infusion Solutions
- Gels
- Sprays
- Biomedical Sealants
Therapeutic Indication
- Immunology
- Oncology
- Pulmonology
- Rheumatology
- Transplantation
- Neurology
- Hematology
- Other
Application
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- Hemophilia
- Von Willebrand's Disease (vWD)
- Others
End-User
- Clinics
- Hospitals
- Other
Singapore Blood Plasma Market Regional Analysis/Insights
The Singapore blood plasma market is analyzed and market size insights and trends are provided type, mode of delivery, therapeutic indication, application, and end-user as referenced above.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Singapore blood plasma market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2020.
Competitive Landscape and Singapore Blood Plasma Market Share Analysis
The Singapore blood plasma market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the Singapore blood plasma market are:
- CSL Limited (Australia)
- Grifols, S.A. (Spain)
- Takeda Pharmaceutical Company Limited (Japan)
- Octapharma AG (Switzerland)
SKU-